ODI Pharma AB (XSAT:ODI) Retained Earnings: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:ODI ODI Pharma AB XSAT:ODI
46 GF Score
Price kr2.34
GF Value kr9.70
Valuation Significantly Undervalued
View Full Analysis

What is ODI Pharma AB Retained Earnings?

ODI Pharma AB XSAT:ODI +2.63% 46 Retained Earnings is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.70 (Significantly Undervalued).

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. ODI Pharma AB's retained earnings for the quarter that ended in Mar. 2026 was kr0.00 Mil.


ODI Pharma AB  (XSAT:ODI) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


ODI Pharma AB Retained Earnings Historical Data

* Premium members only.

The historical data trend for ODI Pharma AB's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ODI Pharma AB Retained Earnings Chart

ODI Pharma AB Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Retained Earnings
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ODI Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSAT:ODI
46GF Score
ODI Pharma AB XSAT:ODI
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ODI Pharma AB Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of kr0.00 Mil mean?
ODI Pharma AB (XSAT:ODI) has a Retained Earnings of kr0.00 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on ODI Pharma AB and its competitors.
Is ODI Pharma AB's Retained Earnings too high?
ODI Pharma AB's current Retained Earnings is kr0.00 Mil. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's Retained Earnings compare to ZTS and UTHR?
ODI Pharma AB's Retained Earnings of kr0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on ODI Pharma AB and its competitors. ODI Pharma AB's current Retained Earnings is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.70, compared to a current price of kr2.34 — trading 75.9% below its estimated fair value. The current Retained Earnings is kr0.00 Mil. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Retained Earnings is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?

Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued. The current stock price of kr2.34 is trading 75.9% below its estimated GF Value™ of kr9.70. GuruFocus considers ODI Pharma AB to be Significantly Undervalued.

Key valuation signals for XSAT:ODI:

  • Retained Earnings: kr0.00 Mil
  • GF Value™: kr9.70 vs. price of kr2.34 (75.9% below fair value)
  • GF Score™: 46/100

No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ODI Pharma AB Business Description

Address Ostermalmstorg 1, Stockholm, SWE, 114 42
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
46GF Score

Get the complete analysis for XSAT:ODI

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.34
Price
kr9.70
GF Value